Cocrystal Pharma

Recent papers from Cocrystal Pharma

1. Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label studyJournal of Medical Virology · 2020
2. Discovery of a Series of 2′-α-Fluoro,2′-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C VirusJournal of Medicinal Chemistry · 2019
3. Synthesis of (2S)-2-Chloro-2-fluororibolactone via Stereoselective Electrophilic FluorinationThe Journal of Organic Chemistry · 2017
4. 2′-Chloro,2′-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in CultureJournal of Medicinal Chemistry · 2017
5. Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA PolymeraseAntimicrobial Agents and Chemotherapy · 2017
6. Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094Antimicrobial Agents and Chemotherapy · 2016
7. A laboratory-scale continuous flow chlorine generator for organic synthesisReaction Chemistry & Engineering · 2016
8. Synthesis and Evaluation of 2,6-Modified Purine 2′-C-Methyl Ribonucleosides as Inhibitors of HCV ReplicationACS Medicinal Chemistry Letters · 2015
9. Synthesis and antiviral evaluation of 2′,3′-dideoxy-2′,3′-difluoro-D-arabinofuranosyl 2,6-disubstituted purine nucleosidesHeterocyclic Communications · 2015
10. β-d-2′-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5′-Triphosphate FormsJournal of Medicinal Chemistry · 2015